Skip to content

Efficacy and safety of Bacillus Calmette Guerin (BCG) vaccine and Purified protein derivative (PPD)in treatment of viral warts

A double blind randomized control trial to compare the effectiveness, safety and tolerability of bacillus-calmette-guerin (BCG) vaccine and purified protein derivative (PPD) of tuberculin antigen in the treatment of multiple viral warts.

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2014/12/005244
Enrollment
60
Registered
2014-12-03
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Multiple viral warts

Interventions

Intervention1: Bacillus-calmette-guerin (BCG) vaccine: Freeze dried, powdered form of BCG vaccine is taken and diluted with 1 ml of normal saline, supplied with the vial of BCG vaccine. After preparat

Sponsors

Medical College Kolkata
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: i. Male or female patients between 18 and 65 years of age (both inclusive) ii. Multiple viral warts (number > 10) iii. Patients who give their informed consent

Exclusion criteria

Exclusion criteria: i. Pregnant or lactating women ii. Any evidence of immunosuppression (egg HIV infection, Organ transplantation, long term steroid use etc.) iii. Any other systemic disease (egg liver, kidney disorder) iv. Patients not giving their informed consent v. Presence of mucosal wart(s)

Design outcomes

Primary

MeasureTime frame
Number of wartsTimepoint: Baseline, 1, 2, 3, 4, 5, 6th month. Every patient will be given treatment for 3 months (either BCG or PPD according to randomization) at monthly intervals. They will be followed up for the next 3 months, total study duration of 6 months.

Secondary

MeasureTime frame
Serum for Liver Function Test, urea, creatinine, Hemoglobin, Total count, Differential Count, Erythrocyte Sedimentation RateTimepoint: Screening visit, 3rd month visit

Countries

India

Contacts

Public ContactAmrita Sil

Medical College Kolkata

drdasnilay@gmail.com9433394148

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026